Cipla’s Umang Vohra on Covid-19 portfolio, upcoming drugs, US business outlook, and more.


The Medicine Box Podcast: CNBC-TV18’s Ekta Batra chats with Cipla MD and Global CEO Umang Vohra about the pharma company’s plan to capture a bigger share of the U.S. market, its COVID-19 portfolio, its new products, its growth prospects and more.

Robinhood of the pharmaceutical industry, Cipla is looking to increase its presence in the US market, the company’s Managing Director and Global CEO, Umang Vohra.

In this edition of The Medicine Box podcast, CNBC-TV18’s Ekta Batra talks to Vohra about Cipla’s plan to capture a bigger share of the U.S. market, the company’s COVID-19 portfolio – from tocilizumab to remdesivir to favipiravir, new products, growth prospects and Continuation.

Cipla, which is India’s third-largest pharmaceutical company and operates in more than 80 countries with more than 46 manufacturing facilities, seeks to manufacture complex drugs and injectables in the respiratory and cancer segments, Vohra said.

Tune in to The Medicine Box podcast for more


Not all news on the site expresses the point of view of the site, but we transmit this news automatically and translate it through programmatic technology on the site and not from a human editor.
Back to top button